Page last updated: 2024-10-29

indolepropanol phosphate and Carcinoma, Papillary

indolepropanol phosphate has been researched along with Carcinoma, Papillary in 1 studies

indolepropanol phosphate: binds specifically to the alpha subunit, but not to the beta subunit of tryptophan synthase
3-(indol-3-yl)propyl phosphate : An monoalkyl phosphate compound having an O-3-(indol-3-yl)propyl substituent.

Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Varinelli, L1
Caccia, D1
Volpi, CC1
Caccia, C1
De Bortoli, M1
Taverna, E1
Gualeni, AV1
Leoni, V1
Gloghini, A1
Manenti, G1
Bongarzone, I1

Other Studies

1 other study available for indolepropanol phosphate and Carcinoma, Papillary

ArticleYear
4-IPP, a selective MIF inhibitor, causes mitotic catastrophe in thyroid carcinomas.
    Endocrine-related cancer, 2015, Volume: 22, Issue:5

    Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cell Cycle; Cell P

2015